Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 19, Issue 3, Pages 644-649
Publisher
Oxford University Press (OUP)
Online
2013-01-11
DOI
10.1097/mib.0b013e318280ebbd
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease
- (2011) Harminder Singh et al. GASTROENTEROLOGY
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease
- (2010) R. PANACCIONE et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
- (2010) Gary R. Lichtenstein et al. Clinical Gastroenterology and Hepatology
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
- (2010) Mario Cottone et al. Clinical Gastroenterology and Hepatology
- AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
- (2010) Francis A. Farraye et al. GASTROENTEROLOGY
- Cancer in Crohnʼs Disease patients treated with infliximab: A long-term multicenter matched pair study
- (2010) Livia Biancone et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice
- (2009) Y. ZABANA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
- (2009) Millie D. Long et al. Clinical Gastroenterology and Hepatology
- Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
- (2008) Sarah Caspersen et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Serious Events with Infliximab in Patients with Inflammatory Bowel Disease
- (2008) Hilbert S de Vries et al. DRUG SAFETY
- Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study
- (2008) Harminder Singh et al. GASTROENTEROLOGY
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
- (2008) H Fidder et al. GUT
- Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer
- (2008) Kenneth J Chang et al. Nature clinical practice. Gastroenterology & hepatology
- Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease
- (2007) Sunanda Kane et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started